BANGALORE: Biocon Ltd, India's top listed biotechnology firm, expects its branded formulations business in India to double this fiscal year as it
launches new products, its chairman said.
Biocon, which makes insulin, cholesterol-lowering statins and other branded drugs, is also talking to companies to license out its oral insulin, the clinical trials of which are expected to end in March next year, Kiran Mazumdar-Shaw told Reuters in an interview on Tuesday.
http://economictimes.indiatimes.com/News/News-By-Industry/Healthcare-/-Biotech/Biocon-sees-India-biz-growth-boost-from-Mylan-pact/articleshow/4935449.cms
Tuesday, September 8, 2009
Subscribe to:
Post Comments (Atom)
It was really a nice article and i was really impressed by reading this article
ReplyDeleteclinical data management
clinical data management Training